Presentations – COLDA 2019


Day 1 - Thursday, 19 September 2019

 Parallel Sessions - Integrated training on:
 Basic colonoscopy
(No slides or video available)
Manar Salah, Ain Shams University, Egypt

Basic upper endoscopy
(No slides or video available)

Ahmed Talaat Elganzory, Ain Shams University, Egypt


Point of care testing
(Not yet available)

Elena Ivanova Reipold, FIND, Switzerland
Cynthia Tamandjou, University of Cape Town, South Africa
Shivraj Bhoite, Molbio Diagnostics, India
Marc Amphlett, Genedrive, United Kingdom
Sushma Patel, Cepheid, France

 Opening session: Opening of the conference
Chairs: Manal El-Sayed, MD, PhD

Keynote lecture: Global efforts on viral hepatitis elimination
John Ward, MD
Centers for Disease Control, USA


What’s new in viral hepatitis - including EASL coverage
Thomas Berg, MD
University Hospital Leipzig, Germany


Viral hepatitis and pregnancy
Wendy Spearman, MD, PhD
University of Cape Town, South Africa

 Session 1: HCC and its management
Chairs: Olufunmilayo Lesi, FWACP, FMCP

Epidemiology, burden of disease and outcomes of HCC in Africa
Edith Okeke, MD
University of Jos, Nigeria


Improving risk stratification and early detection of HCC in Africa
Ashraf Omar, MD
Cairo University, Egypt


Loco-regional therapy for HCC – including ablation, chemoembolization and hepatic artery embolization
Benjamin Sarkodie, MD
University of Ghana School of Medicine & Dentistry, Ghana


Systemic therapy – what is realistic in the LMIC setting?
Mitesh Borad, MD
Mayo Clinic Arizona, USA


Surgical therapy for HCC – including resection and liver transplantation
Mahmoud El-Meteini, MD, M.B.B.cH
Ain Shams University, Egypt


Needs for research and advocacy for HCC in Africa
Olufunmilayo Lesi, FWACP, FMCP
WHO Regional Office for Africa, Congo


Day 2 - Friday, 20 September 2019

 Session 2: Management of viral hepatitis (I) - HBV related
Chairs: Wendy Spearman MD, PhD & Thomas Berg, MD
 Simplification of HBV treatment algorithm
(Not yet available)

Ayman Yosry, MD
Cairo University, Egypt

Treatment of HBV in sub-Saharan Africa
Hailemichael Desalegn, MD
St. Paul’s Hospital Millennium Medical College, Ethiopia

 Abstract-driven presentations
(No videos available for abstract-driven presentations)
 Prevalence of Hepatitis B Surface Antigen (HBsAg) positivity and its associated factors in Rwanda/risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program
Jean Damascene Makuza
 Analysis of the National Hepatitis B Viral Load Testing Programme in Uganda
Viola Kasone
 High rates of HBV functional cure among HIV/HBV-coinfected patients on ART in Zambia
Michael Vinikoor
 Session 3: Management of viral hepatitis (II) - HCV related
Chairs: Mark Nelson, MD, FRCP & Mary Afihene MBChB, FWACP

Treatment of hepatitis C in SSA (Rwanda)
Neil Gupta, MD
Harvard Medical School, USA


Hepatitis delta
Mario Rizetto, MD
University of Torino, Italy

 Abstract-driven presentations
(No videos available for abstract-driven presentations)
 Hepatitis C treatment among people who inject drugs in Kenya: preliminary findings of the test and link to care for injecting drug users study C infection in Rwanda: results from a nationwide screening program
Peter Cherutich
 Efficacy of Direct-Acting Antiviral (DAA) regimens in HIV/HCV-coinfected patients in Libya
Nagat Bousifi
 Heading toward hepatitis C virus elimination: Tunisian experience, achievements and prospects
(Not yet available)

Mouna Safer
 Get your paper published in The Lancet
(No permission given to publish)

Robert Brierley
The Lancet Gastroenterology & Hepatology, United Kingdom

HBV Cure Science 101 - organized by ICE-HBV
Anna Kramvis, BScHons, PhD
International Coalition to Eliminate HBV (ICE-HBV) / University of the Witwatersrand, South Africa

 Session 4: Public health - Egypt’s model of care
Chairs: Gamal Esmat, MD & John Ward, MD
 Screening of 50 million people
(Not yet available)

Manal El-Sayed, MD, PhD
Ain Shams University, Egypt
 Scaling up treatment
(No permission given to publish)

Wahid Doss, MD
Cairo University, Egypt
 Round Table discussion: Translation of Egypt’s experience to the rest of Africa
(Not yet available)
Wahid Doss, MD - Cairo University, Egypt
Gamal Esmat, MD - Cairo University, Egypt
Magdy El-Serafy, MD - Cairo University, Egypt
Imam Waked, MB, BCh, MSc, MD, FAASLD - National Liver Institute, Egypt
Mohamed Hassany, MD - National Hepatology and Tropical Medicine Research Institute, Egypt
Jean Damascene Makuza, MD - Rwanda Biomedical Center, Rwanda
 Session 5: Civil society contribution in Africa - organized by World Hepatitis Alliance
Chairs: Cary James & Gamal Shiha, MD, MBBH, MSc
 Round table Discussion: the role of patient support groups 

Cary James - World Hepatitis Alliance, United Kingdom

 Mohamed El-Wahsh - Tanya Masr, Egypt


Ammal Metwally, MD, PhD - National Research Center, Egypt


Coulibaly Alioune Badara, MD - Association pour la Promotion de la Sante et le Developpement (APSAD), Mali


Kenneth Kabagambe, BA - The National Organisation for People Living with Hepatitis B (NOPLHB), Uganda


Elodie Sanasee - Prévention Information et Lutte contre le SIDA (PILS), Mauritius


Day 3 - Saturday, 21 September 2019

 Session 6: NASH/NAFLD management in Africa
Chairs: John Rwegasha MBChB, M.MED, FRCP, MSc & Imam Waked, MB, BCh, MSc, MD, FAASLD

New therapies for NASH/NAFLD
Thomas Berg, MD
University Hospital Leipzig, Germany


Clinical case presentation
Imam Waked, MB, BCh, MSc, MD, FAASLD
National Liver Institute, Egypt

 Abstract-driven presentations
(No videos available for abstract-driven presentations)
 HCC developed following DAAs treatment does not display more aggressive pattern
(Not yet available)

Gamal Shiha
 Factors associated with liver toxicity among HIV infected children and adolescents attending a national referral pediatric HIV clinic in Uganda
Bonny Mulindwa
 Prevalence of fatty liver disease and associated factors among outpatients attending internal medicine clinics at Muhimbili University of Health and Allied Sciences Academic Medical Centre, Tanzania
Nontobeko Simelane
 Session 7: WHO sponsored session on viral hepatitis and universal health coverage

The global and regional hepatitis elimination agenda
Joumana Hermez


Access to hepatitis B and C medicines
Morgane Ahmar
International Treatment Preparedness Coalition (ITPC), Morocco


Leaving no one behind: role of civil society in reaching people who inject drugs (PWID) for hepatitis elimination
Elie Aaraj
Middle East and North Africa Harm Reduction Association (MENAHRA), Lebanon


Innovative financing and financial protection: inclusion of viral hepatitis services
Awad Mataria, PhD

 Fitting viral hepatitis elimination in the UHC agenda
(Not yet available)

Awad Mataria, PhD
 Closure of the conference
(Videos to be published)

Closure of the conference

Manal El-Sayed & Charles Boucher
Ain Shams University, Egypt & Erasmus Medical Center, the Netherlands

 President of Ain Shams University speech
Mahmoud El-Meteini
Ain Shams University, Egypt
 Minister of Health speech
Her Excellency Dr. Hala Zayed
Ministry of Health, Egypt
 Minister of Investment and International Cooperation speech
Her Excellency Dr. Sahar Nasr
Ministry of Investment and International Coorperation, Egypt
 Minister of Higher Education speech
His Excellency Prof. Khaled Abdel-Ghaffar
Ministry of Higher Education, Egypt